Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics Inc (NQ: FDMT )

16.85 -0.83 (-4.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 250,651
Open 17.64
Bid (Size) 16.85 (2)
Ask (Size) 19.32 (1)
Prev. Close 17.68
Today's Range 16.79 - 17.71
52wk Range 5.320 - 26.49
Shares Outstanding 33,234,357
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Expert Ratings for 4D Molecular Therapeutics
 
Via Benzinga
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
-18.36%
-18.36%
1 Month
-16.42%
-16.42%
3 Month
-18.80%
-18.80%
6 Month
+100.60%
+100.60%
1 Year
+7.46%
+7.46%

More News

Read More
4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study
Via Benzinga
4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
Analyst Ratings for 4D Molecular Therapeutics
Via Benzinga
Expert Ratings for 4D Molecular Therapeutics
Via Benzinga
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
How Is The Market Feeling About 4D Molecular Therapeutics?
Via Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
From 4D Molecular Therapeutics, Inc.
Via Globe NewsWire
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
Via The Motley Fool
HC Wainwright Creates Bullish Pitch On 4D Molecular Citing 'Broader Systemic Potential'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Via Benzinga
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
Via Benzinga
Sea, UiPath, J&J Snack Foods And Other Big Gainers From Tuesday
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.